Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S V Rajkumar

Showing results (121-130 of 172) with videos related to

Pageof 18
Sort By:
Leukemia|August 21, 2012
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myelomaT E Witzig, K M Laumann, M Q Lacy, et al.
Leukemia|July 12, 2012
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUSJ A Katzmann, R Clark, R A Kyle, et al.
Bone Marrow Transplantation|July 5, 2016
Autologous stem cell transplant for multiple myeloma patients 70 years or olderE Muchtar, D Dingli, S Kumar, et al.
Blood Cancer Journal|March 21, 2015
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantationV Roy, A K Stewart, P L Bergsagel, et al.
Blood Cancer Journal|October 21, 2017
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination SurveyO Landgren, B I Graubard, S Kumar, et al.
Leukemia|May 29, 2010
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studyS K Kumar, I Flinn, S J Noga, et al.
Leukemia|May 24, 2016
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agentsN Majithia, S V Rajkumar, M Q Lacy, et al.
Leukemia|October 7, 2006
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myelomaR Fonseca, S A Van Wier, W J Chng, et al.
Leukemia|October 26, 2013
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsS K Kumar, A Dispenzieri, M Q Lacy, et al.
Leukemia|August 15, 2015
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myelomaS K Kumar, E Ma, A E Engebretson, et al.
Pageof 18

Showing results (121-130 of 172) with videos related to

Sort By:
Pageof 18
Leukemia|August 21, 2012
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myelomaT E Witzig, K M Laumann, M Q Lacy, et al.
Leukemia|July 12, 2012
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUSJ A Katzmann, R Clark, R A Kyle, et al.
Bone Marrow Transplantation|July 5, 2016
Autologous stem cell transplant for multiple myeloma patients 70 years or olderE Muchtar, D Dingli, S Kumar, et al.
Blood Cancer Journal|March 21, 2015
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantationV Roy, A K Stewart, P L Bergsagel, et al.
Blood Cancer Journal|October 21, 2017
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination SurveyO Landgren, B I Graubard, S Kumar, et al.
Leukemia|May 29, 2010
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studyS K Kumar, I Flinn, S J Noga, et al.
Leukemia|May 24, 2016
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agentsN Majithia, S V Rajkumar, M Q Lacy, et al.
Leukemia|October 7, 2006
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myelomaR Fonseca, S A Van Wier, W J Chng, et al.
Leukemia|October 26, 2013
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsS K Kumar, A Dispenzieri, M Q Lacy, et al.
Leukemia|August 15, 2015
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myelomaS K Kumar, E Ma, A E Engebretson, et al.
Pageof 18